Active surveillance with selective radical treatment for localized prostate cancer

Cancer Journal

Volumn 13, Issue 5, 2007, Pages 289-294

  Van As, Nicholas J ^a   Parker, Chris C ^a,b  

^a Royal Marsden Hospital   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Active surveillance; Prostate cancer; Watchful waiting

Indexed keywords

CANCER LOCALIZATION; CANCER PATIENT; EXTERNAL BEAM RADIOTHERAPY; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; AGE; BLOOD; DISEASE COURSE; MALE; MORTALITY; PATHOLOGY; PROSTATE TUMOR; RISK ASSESSMENT;

PROSTATE SPECIFIC ANTIGEN;

AGE FACTORS; DISEASE PROGRESSION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 38449093363     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318156ff65     Document Type: Review

References (33)

1. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005; 352:1977-1984.
2. Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975-980.
3. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
4. Zelefsky MJ, Lyass O, Fuks Z, et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant andro- gen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol. 1998;16:3380-3385.
5. Chism DB, Hanlon AL, Horwitz EM, et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:380-385.
6. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790-796.
7. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781-789.
8. Singer PA, Tasch ES, Stocking C, et al. Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol. 1991;9:328-334.
9. Draisma G, Boer R, Otto S, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868-878.
10. Parker C, Muston D, Melia J, et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer. 2006;94:1361-1368.
11. Choo R, DeBoer G, Klotz L, et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys. 2001;50:615-620.
12. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol. 2005;23:8165-8169.
13. Ali K, Gunnar A, Jan-Erik D, et al. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer. 2007;120:170-174.
14. Carter HB, Walsh PC, Landis P, et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002;167:1231-1234.
15. de Vries SH, Raaijmakers R, Kranse R, et al. Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy. J Urol. 2004;172:2193-2196.
16. Hardie C, Parker C, Norman A, et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int. 2005;95:956-960.
17. van As N, Norman A, Woode-Amissah R, et al. Active surveillance of low risk localized prostate cancer: baseline predictors of disease progression. Paper presented at: 2007 Prostate Cancer Symposium; Orlando, FL, February 2007. Abstract 319.
18. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst. 2007;99:526-532.
19. Venkitaraman R, Norman A, Woode-Amissah R, et al. Predictors of histological disease progression in untreated, localized prostate cancer. J Urol. 2007;178:833-837.
20. Khan MA, Carter HB, Epstein JI, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003;170: 2274-2278.
21. Kahn T, Burrig K, Schmitz-Drager B, et al. Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation. Radiology. 1989;173:847-851.
22. Sommer FG, Nghiem HV, Herfkens R, et al. Determining the volume of prostatic carcinoma: value of MR imaging with an external-array coil. AJR Am J Roentgenol. 1993;161:81-86.
23. Jager GJ, Ruijter ET, van de Kaa CA, et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol. 1996;166:845-852.
24. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology. 2002;223:91-97.
25. Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North Am. 2000;38:59-85, viii.
26. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804-814.
27. Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging. 2004;20:654-661.
28. Shukla-Dave A, Hricak H, Kattan MW, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int. 2007;99:786-793.
29. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging. 2005;21:258-262.
30. deSouza N, Riches S, van As N, et al. Potential value of diffusion weighted imaging as an indicator of tumor aggressiveness in prostate cancer. Proc Intl Soc Mag Reson Med. 2007;15:3659.
31. Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localised prostate cancer. Cancer 1995;75(Suppl):1963-1968.
32. Donovan J, Hamdy F, Neal D, et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7: 1-88.
33. Yatani R, Shiraishi T, Nakakuki K, et al. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer Inst. 1988;80:683-687.